Pacira BioSciences Inc (PCRX)

Pacira BioSciences Inc Aktie (PCRX) Neueste Nachrichten

National Bank of Canada FI Takes Position in Pacira BioSciences, Inc. (NASDAQ:PCRX) - MarketBeat

MarketBeat

National Bank of Canada FI Purchases New Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX) - Defense World

Defense World

Moving Average Crossover Alert: Pacira BioSciences (PCRX) - Yahoo Singapore News

Yahoo Singapore News

Pacira BioSciences, Inc. (NASDAQ:PCRX) Given Average Recommendation of "Buy" by Analysts - MarketBeat

MarketBeat

Moving Average Crossover Alert: Pacira BioSciences (PCRX) - Yahoo Singapore News

Yahoo Singapore News

Pacira BioSciences Reports First Quarter 2024 Financial Results and Announces $150 Million Share Repurchase ... - br.ADVFN.com

br.ADVFN.com

Pacira BioSciences, Inc. (NASDAQ:PCRX) Receives Consensus Rating of “Buy” from Analysts - Defense World

Defense World

Pacira (PCRX) Misses Q2 Earnings and Revenue Estimates - Yahoo Movies UK

Yahoo Movies UK

Pacira BioSciences (NASDAQ:PCRX) Sees Strong Trading Volume - Defense World

Defense World

Pacira BioSciences (NASDAQ:PCRX) Price Target Lowered to $43.00 at Needham & Company LLC - Defense World

Defense World

Pacira announces $250 million convertible notes offering - Investing.com India

Investing.com India

Pacira (PCRX) Lags Q1 Earnings Estimates - Yahoo Canada Shine On

Yahoo Canada Shine On

Earnings Preview: Pacira (PCRX) Q1 Earnings Expected to Decline - Yahoo Canada Shine On

Yahoo Canada Shine On

Pacira (PCRX) Lags Q3 Earnings Estimates - Yahoo Singapore News

Yahoo Singapore News

Pacira BioSciences, Inc. Just Missed Earnings - But Analysts Have Updated Their Models - Simply Wall St

Simply Wall St

Earnings Miss: Pacira BioSciences, Inc. Missed EPS By 17% And Analysts Are Revising Their Forecasts - Yahoo Finance UK

Yahoo Finance UK

Pacira (PCRX) Q4 Earnings and Revenues Beat Estimates - Yahoo Canada Shine On

Yahoo Canada Shine On

Pacira BioSciences, Inc. Announces Pricing of $250.0 Million Aggregate Principal Amount of 2.125% Convertible ... - GlobeNewswire

GlobeNewswire

Pacira BioSciences, Inc. Announces Pricing of $250.0 Million Aggregate Principal Amount of 2.125% Convertible ... - Yahoo Finance

Yahoo Finance

Pacira BioSciences' (PCRX) Buy Rating Reaffirmed at HC Wainwright - Defense World

Defense World

Pacira BioSciences (NASDAQ:PCRX) Sees Unusually-High Trading Volume - MarketBeat

MarketBeat

Pacira BioSciences (NASDAQ:PCRX) Given Buy Rating at HC Wainwright - MarketBeat

MarketBeat

Pacira BioSciences (NASDAQ:PCRX) PT Lowered to $38.00 - MarketBeat

MarketBeat

Pacira BioSciences, Inc. Announces Proposed Offering of $250.0 Million Aggregate Principal Amount of Convertible ... - GlobeNewswire

GlobeNewswire

Pacira BioSciences, Inc. Announces Proposed Offering of $250.0 Million Aggregate Principal Amount of Convertible Senior Notes

GlobeNewswire Inc.

Pacira (PCRX) Q1 Earnings Miss, Exparel Sales Drive Revenues - MSN

MSN

Analyst Ratings For Pacira BioSciences - Pacira BioSciences (NASDAQ:PCRX) - Benzinga

Benzinga

Pacira BioSciences up 12% on stock buyback, Q1 top-line beat - Seeking Alpha

Seeking Alpha

Pacira (PCRX) Q1 Earnings Miss, Exparel Sales Drive Revenues - Yahoo Finance Australia

Yahoo Finance Australia

Pacira (PCRX) Q1 Earnings Miss, Exparel Sales Drive Revenues - Zacks Investment Research

Zacks Investment Research

Pacira BioSciences, Inc. (NASDAQ:PCRX) Q1 2024 Earnings Call Transcript - Insider Monkey

Insider Monkey

Pacira BioSciences, Inc. (NASDAQ:PCRX) Q1 2024 Earnings Call Transcript - Insider Monkey

Insider Monkey

Pacira reports solid Q1 earnings, announces $150 million buyback - Investing.com India

Investing.com India

Earnings call: Pacira BioSciences maintains positive outlook in Q1 2024 - Investing.com Australia

Investing.com Australia

Pacira reports solid Q1 earnings, announces $150 million buyback - Investing.com Canada

Investing.com Canada

Pacira reports solid Q1 earnings, announces $150 million buyback - Investing.com

Investing.com

Earnings call: Pacira BioSciences maintains positive outlook in Q1 2024 - Investing.com India

Investing.com India

Russell Investments Group Ltd. Sells 123756 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) - Defense World

Defense World

Earnings call: Pacira BioSciences maintains positive outlook in Q1 2024 - Investing.com UK

Investing.com UK

Pacira reports solid Q1 earnings, announces $150 million buyback - Investing.com Australia

Investing.com Australia

Pacira (PCRX) Q1 Earnings Miss, Exparel Sales Drive Revenues - Zacks Investment Research

Zacks Investment Research

Pacira BioSciences Inc (PCRX) (Q1 2024) Earnings Call Transcript Highlights: Strategic Growth and Robust Sales ... - GuruFocus.com

GuruFocus.com

Iceberg Image Closes Pacira Drug Patent Infringement Trial - Law360

Law360

Pacira BioSciences, Inc. 2024 Q1 - Results - Earnings Call Presentation (NASDAQ:PCRX) - Seeking Alpha

Seeking Alpha

Pacira BioSciences Reports Q1 2024 Results: Aligns with EPS Projections and Announces $150 ... - Yahoo Finance

Yahoo Finance

Here's What Key Metrics Tell Us About Pacira (PCRX) Q1 Earnings - Yahoo Finance

Yahoo Finance

Pacira reports solid Q1 earnings, announces $150 million buyback - Investing.com UK

Investing.com UK

Pacira BioSciences Reports First Quarter 2024 Financial Results and Announces $150 Million Share Repurchase ... - wallstreet:online

wallstreet:online

Pacira BioSciences Reports First Quarter 2024 Financial Results and Announces $150 Million Share Repurchase program

GlobeNewswire Inc.

Pacira BioSciences to Participate in Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference - Yahoo Finance

Yahoo Finance